Φορτώνει......
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Surg Case Rep |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Berlin Heidelberg
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/ https://ncbi.nlm.nih.gov/pubmed/29524063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|